Moleculin Biotech, Inc. 10-Q

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS    During the three months ended June 30, 2022, the Company issued warrants to purchase 50,000 shares of common stock with an exercise price of $1.49 per share to two entities providing clinical trial advisory services, which warrants will vest annually over four years while services are being performed. The foregoing securities were issued pursuant to Section 4(a)(2) of the Securities Act.   ITEM 3. DEFAULTS UPON SENIOR SECURITIES   None.   ITEM 4. MINE SAFETY DISCLOSURE   Not applicable.